Authors : Md. Abu Horaira Sarder

Volume/Issue : Volume 11 - 2026, Issue 6 - June

Google Scholar : https://tinyurl.com/3a3um4mf

Scribd : https://tinyurl.com/78yth82f

DOI : https://doi.org/10.38124/ijisrt/26jun1335

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Hematopoiesis is the maturation of hematopoietic stem cells into blood cells. This process takes place in different places during the early embryo. During the third week of human embryogenesis, a group of mesenchymal cells in the yolk sac forms clusters called blood islands. These islands have central cells that differentiate to form primitive blood-forming cells, and peripheral cells that form a primitive vascular system. Some of these cells become primitive erythroblasts, the first cells to produce hemoglobin. These cells are not promyelocytes, but they do not develop into erythrocytes as do the adult bone marrow pronormoblasts. In the third month of embryonic development, stem cells migrate to the liver, which becomes the primary site of blood cell production. Hematopoiesis is also accomplished in the spleen, lymph nodes, and thymus. By the fourth month of gestation, bone marrow hematopoiesis begins, and by birth it is the main source of blood cell production. The process of hematopoiesis in bone marrow is called medullary hematopoiesis, and the process of the creation of blood cells outside the bone marrow is called extramedullary hematopoiesis. Hematopoiesis is present in almost all bones at birth. In adults, it occurs primarily in flat bones (sternum, ribs, skull, and vertebrae) and in the ends of long bones. When demand is high, the marrow might reappear in other sites. Extramedullary hematopoiesis normally diminishes after birth, but can happen in the liver or spleen in certain diseases. In the bone marrow, nutrient arteries give rise to arterioles and sinusoids, which supply the blood cell-forming cells. The marrow stroma is the site of erythropoiesis, granulopoiesis, and thrombopoiesis. The release of blood cells from marrow into circulation is a crucial step, and occurs when mature blood cells pass through the walls of the sinusoids into the blood. This is essential but not well understood.

References :

1. E. Martínez-Quintana and F. Rodríguez-González, "Anemia in adult congenital heart disease: Prevalence and markers of iron deficiency," International Journal of Cardiology, vol. 157, no. 3, pp. 461–462, 2012.
2. S. Munir, S. Ahmed, M. Ahmed, and T. Naru, "Hematological and biochemical profile in β-thalassemia female patients," Pakistan Journal of Medical Sciences, vol. 29, no. 5, pp. 1211–1214, 2013.
3. J. M. Guralnik, R. S. Eisenstaedt, L. Ferrucci, H. G. Klein, and R. C. Woodman, "Prevalence of anemia in persons 65 years and older in the United States: Evidence for a high rate of unexplained anemia," Blood, vol. 104, no. 8, pp. 2263–2268, 2004.
4. F. Tradati, "Risk of hepatocellular carcinoma in chronic hepatitis C patients undergoing hemodialysis: A multicenter prospective study," Kidney International, vol. 54, no. 6, pp. 2147–2153, 1998.
5. V. Laosombat et al., "Clinical and molecular characterization of β⁰-thalassemia frameshift -41/42 mutation in Thai patients," Journal of Pediatric Hematology/Oncology, vol. 23, no. 6, pp. 396–400, 2001.
6. E. Angelucci et al., "Italian guidelines for the management of iron overload in thalassemia major: An analytical hierarchy process approach," Haematologica, vol. 93, no. 8, pp. 1242–1246, 2008.
7. S. Birndorf, P. Czerniak, and S. Nudelman, "A hybrid expert system for diagnosing microcytic anemia," Computer Methods and Programs in Biomedicine, vol. 50, no. 3, pp. 227–234, 1996.
8. S. T. Chou et al., "RH and Kell antigen-matched transfusion in sickle cell disease patients reduces alloimmunization," Blood, vol. 135, no. 7, pp. 550–565, 2020.
9. V. Brancaleoni, E. Di Pierro, I. Motta, and L. Forni, "Laboratory approach to the diagnosis of thalassemia," Blood Reviews, vol. 30, no. 1, pp. 65–73, 2016.
10. M. Rahaman et al., "Prevalence and hematological characteristics of Hb E/β-thalassemia in Brunei Darussalam: A retrospective analysis," Asian Journal of Transfusion Science, vol. 16, no. 1, pp. 45–51, 2022.
11. A. R. Cohen et al., "Iron chelation therapy and assessment of cardiac iron using T2 MRI in thalassemia," Annals of the New York Academy of Sciences, vol. 1054, pp. 204–213, 2005.
12. V. Heves-Girard et al., "Desmopressin responsiveness in non-severe hemophilia A: Clinical outcomes," Haemophilia, vol. 24, no. 5, pp. 859–867, 2018.
13. M. Franchini et al., "Incidence of cancer in Italian patients with von Willebrand disease: A national survey," Thrombosis and Haemostasis, vol. 113, no. 5, pp. 1010–1014, 2015.
14. R. E. Drews and I. A. Shulman, "Advances in hematology-oncology in 2009: Key updates for internists," Mayo Clinic Proceedings, vol. 85, no. 2, pp. 166–174, 2010.
15. E. Francini et al., "Association between ABO blood group and inhibitor development in severe hemophilia A," Journal of Thrombosis and Haemostasis, vol. 19, no. 3, pp. 725–733, 2021.
16. A. Sayani et al., "Predicting response to anemia therapy: Role of baseline hemoglobin and erythropoietin," Journal of Clinical Nephrology, vol. 29, no. 2, pp. 98–105, 2015.
17. E. Haus, F. Halberg, and G. Cornélissen, "Biological rhythms in hematopoiesis and immune function," Chronobiology International, vol. 1, no. 2, pp. 147–165, 1983.
18. W. W. M. Lam et al., "Iron overload complications and health-related quality of life in transfusion-dependent thalassemia," Quality of Life Research, vol. 30, no. 3, pp. 715–728, 2021.
19. J. D. Rizzo et al., "Use of erythropoiesis-stimulating agents in cancer patients: ASCO/ASH clinical practice guideline update," Journal of Clinical Oncology, vol. 28, no. 33, pp. 4996–5010, 2010.
20. H. L. Muncie and J. Campbell, "Alpha and beta thalassemia: Diagnosis and management," American Family Physician, vol. 80, no. 4, pp. 339–344, 2009.
21. E. Beutler and C. West, "Hematologic differences between African-Americans and whites: The roles of iron deficiency and α-thalassemia," Blood, vol. 106, no. 2, pp. 740–745, 2005.
22. B. S. Bull, J. Breton-Gorius, et al., "Morphology of the erythron," in Hematology, 4th ed., W. J. Williams, E. Beutler, A. J. Erslev, and M. A. Lichtman, Eds. New York, NY, USA: McGraw-Hill, 1990, pp. 297–316.
23. A. J. Erslev, "Production of erythrocytes," in Hematology, 4th ed., W. J. Williams, E. Beutler, A. J. Erslev, and M. A. Lichtman, Eds. New York, NY, USA: McGraw-Hill, 1990, pp. 389–398.
24. W. Fried, "Factors that affect the rate of erythropoietin production by extrarenal sites," Annals of the New York Academy of Sciences, vol. 554, pp. 1–8, 1989.
25. G. R. Johnson, "Erythropoietin," British Medical Bulletin, vol. 45, pp. 506–514, 1989.
26. P. A. Keown, "Recombinant human erythropoietin: From concept to clinic," Transplantation Proceedings, vol. 21, Suppl. 2, pp. 49–53, 1989.
27. W. Jelkmann and G. Wiedemann, "Serum erythropoietin level: Relationships to blood hemoglobin concentration and erythrocytic activity of the bone marrow," Klinische Wochenschrift, vol. 68, pp. 403–407, 1990.